Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Methotrexate
Drug ID BADD_D01418
Description Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis.[A180322] This inhibition leads to suppression of inflammation as well as prevention of cell division.[A180322] Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma.[A180322,L7144,L7147,L7150,L7180] Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients are intolerant of those treatments.[L7180] Methotrexate was granted FDA approval on 7 December 1953.[L7198]
Indications and Usage Methotrexate oral solution is indicated for pediatric acute lymphoblastic leukemia and pediatric polyarticular juvenile idiopathic arthritis.[L7144] Methotrexate injections for subcutaneous use are indicated for severe active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and severe, recalcitrant, disabling psoriasis.[L7147,L7150,L10457] Other formulations are indicated to treat gestational choriocarcinoma, chorioadenoma destruens, hydatiform mole, breast cancer, epidermoid cancer of the head and neck, advanced mycosis fungoides, lung cancer, and advanced non-Hodgkin's lymphoma.[L7180] It is also used in the maintenance of acute lymphocytic leukemia.[L7180] Methotrexate is also given before treatment with leucovorin to prolong relapse-free survival following surgical removal of a tumour in non-metastatic osteosarcoma.[L7180]
Marketing Status approved
ATC Code L01BA01; L04AX03
DrugBank ID DB00563
KEGG ID D00142
MeSH ID D008727
PubChem ID 126941
TTD Drug ID D0SV8E
NDC Product Code 49452-4601; 51927-1565; 0143-9516; 51285-369; 59137-510; 61703-408; 66220-807; 66220-822; 69238-1423; 12780-0491; 46014-1023; 51407-121; 54436-025; 61703-350; 66220-810; 71335-1772; 46014-1005; 16729-277; 0143-9518; 0143-9519; 50268-527; 51079-670; 70771-1058; 70518-1398; 0555-0572; 0143-9367; 66220-815; 70518-3263; 0703-3675; 58623-0040; 0143-9517; 0143-9830; 54436-020; 59137-505; 59137-535; 59137-540; 0378-0014; 66220-825; 42291-505; 47781-482; 52652-2001; 54436-012; 54436-015; 54436-022; 59137-515; 59137-550; 66220-812; 66220-820; 71335-1118; 50090-5457; 51285-368; 54436-010; 59137-520; 59651-182; 68382-775; 0703-3671; 16729-486; 51285-366; 51285-367; 59137-525; 59137-530; 61703-124; 46014-1133; 63660-0006; 66220-817; 70518-3672; 0703-3678; 0904-7141; 54436-017
UNII YL5FZ2Y5U1
Synonyms Methotrexate | Amethopterin | Methotrexate, (D)-Isomer | Methotrexate, (DL)-Isomer | Mexate | Methotrexate Sodium | Sodium, Methotrexate | Methotrexate, Sodium Salt | Methotrexate, Disodium Salt | Methotrexate Hydrate | Hydrate, Methotrexate | Methotrexate, Dicesium Salt | Dicesium Salt Methotrexate
Chemical Information
Molecular Formula C20H22N8O5
CAS Registry Number 59-05-2
SMILES CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Thyroid cancer16.24.03.001; 05.02.05.001--Not Available
Haematological malignancy01.13.01.003; 16.21.01.002--Not Available
Treatment failure08.06.01.0170.100291%Not Available
Liver injury12.01.17.012; 09.01.07.0220.003286%Not Available
Regurgitation07.01.07.0040.000114%Not Available
Cytotoxic oedema17.07.02.0060.000114%Not Available
Pharyngeal disorder22.04.05.007--Not Available
Herpes simplex hepatitis11.05.02.006; 09.01.09.002--Not Available
Organising pneumonia22.01.02.008--Not Available
Adverse reaction08.06.01.018--Not Available
Type 2 diabetes mellitus14.06.01.003; 05.06.01.003--Not Available
Oral disorder07.05.01.0050.001842%Not Available
Upper airway obstruction22.12.03.032--Not Available
Head and neck cancer16.16.01.003--Not Available
Skin mass23.07.04.0140.001444%Not Available
Renal cell carcinoma20.01.04.003; 16.08.02.002--Not Available
Brain injury19.07.03.007; 17.11.01.003--Not Available
Cholestatic liver injury09.01.07.0160.000114%Not Available
Intellectual disability19.21.06.001; 17.03.07.001--Not Available
Anal pruritus07.03.03.002--Not Available
Hypertransaminasaemia09.01.02.0050.001672%Not Available
Anorectal discomfort07.03.03.003--Not Available
Oropharyngeal discomfort22.12.03.015; 07.05.05.008--Not Available
Oropharyngeal pain22.12.03.016; 07.05.05.004--
X-linked lymphoproliferative syndrome03.17.01.002; 16.21.02.003; 11.05.10.005; 10.03.01.003; 01.13.02.003--Not Available
Epstein-Barr virus associated lymphoproliferative disorder16.21.02.002; 11.05.10.001; 01.13.02.0020.001194%Not Available
Vulvovaginal pain21.08.02.0090.000500%
Acute kidney injury20.01.03.016--
Upper-airway cough syndrome22.12.03.036--
Gastrointestinal tract irritation07.08.03.0080.000580%Not Available
The 29th Page    First    Pre   29 30 31 32 33    Next   Last    Total 37 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene